Condition (MeSH)
Liver Diseases, Parasitic
ClinicalTrials.gov lists 18 trials for Liver Diseases, Parasitic or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Liver Diseases, Parasitic trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2023 | 4 |
| 2022 | 1 |
| 2021 | 3 |
| 2019 | 1 |
| 2013 | 2 |
| 2009 | 1 |
| 2006 | 2 |
| 1999 | 1 |
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Liver Diseases, Parasitic trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 4 |
| Observational | 10 |
How many Liver Diseases, Parasitic trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 2 |
| Completed | 9 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Liver Diseases, Parasitic trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 1 |
Which drugs are being tested for Liver Diseases, Parasitic? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Triclabendazole | 2 |
| Oxfendazole | 1 |
| Diloxanide furoate | 1 |
Interventions as named in the registry (1)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| TREATMENT | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Liver Diseases, Parasitic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Liver abscess | 2 | 1 |
| Adrenal insufficiency | 1 | 1 |
| Cholecystitis | 1 | 1 |
| Dyspnoea | 1 | 1 |
| Gastritis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Liver Diseases, Parasitic? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature. | PLoS neglected tropical diseases | 2021 | Yes |
| Ascariasis in the hepatobiliary system: laparoscopic management. | Journal of the American College of Surgeons | 2008 | Yes |
| Plasmodium falciparum: studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. | Experimental parasitology | 1990 | Yes |
| Cholangiocarcinoma: lessons from Thailand. | Current opinion in gastroenterology | 2008 | No |
| Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. | Stem cells (Dayton, Ohio) | 2006 | No |
Showing 5 of 6 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.